Xeltis is in Swiss Venture Capital Report

Xeltis was in the spotlight this week in the latest Swiss Venture Capital Report, the reference publication for investment in Swiss start-ups. The sector achieved new record overall investment levels and financing rounds last year.

A profile of CEO Laurent Grandidier highlighted how Xeltis’ proven ground-breaking technology has persuaded investors to finance the company in a CHF52 million/EUR45 million round. It was the third-largest in Switzerland last year, setting a European record for medtech startups in 2017.

The report attributed the success to the “forward-looking management of the CEO, who is already working to position the company for the next milestones. The 42-year-old does not see himself as a typical manager: ‘I’m 200% entrepreneur.’”

You can find out more about which cookies we are using or switch them off in settings.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

You can adjust all of your cookie settings by navigating the tabs on the left hand side.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

disable

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.